The National Cancer Institute awarded investigators at Huntsman Cancer Institute a grant totaling more than $3 million to conduct a clinical trial to see if combining creatine monohydrate supplementation and resistance exercise training helps preserve muscle in people who have metastatic prostate cancer.
Reviewed by Lily Ramsey, LLMOct 11 2023 Loss of muscle mass is a major side effect of treatment for prostate cancer. Creatine monohydrate supplementation, a naturally occurring molecule in the body, helps combat fatigue and provides more energy, resulting in better workouts. Researchers hypothesize that taking creatine monohydrate supplementation while participating in resistance training will preserve muscle mass.
"Once patients start receiving treatment for their metastatic prostate cancer, they can no longer gain muscle mass because the treatment blocks the androgen signaling, which helps to make testosterone," says Adriana Coletta, PhD, MS, RD, member of the Cancer Control and Population Sciences Program at Huntsman Cancer Institute, assistant professor in the department of health and kinesiology at the University of Utah, and one of the lead investigators of the clinical trial.
"This is an exceptional collaboration between exercise scientists and top clinical trialists at Huntsman Cancer Institute" says Ulrich. "Together this team will find important answers for men with prostate cancer."
Deutschland Neuesten Nachrichten, Deutschland Schlagzeilen
Similar News:Sie können auch ähnliche Nachrichten wie diese lesen, die wir aus anderen Nachrichtenquellen gesammelt haben.
IU Cancer Center awarded grant to train next generation of cancer drug discovery researchersThe Indiana University Melvin and Bren Simon Comprehensive Cancer Center was awarded a prestigious grant to train the next generation of cancer drug discovery and development researchers.
Weiterlesen »
Suppression of cancer stemness and drug resistance via BRAF/EGFR/MEK inhibition in colorectal cancer cellsA new research paper titled 'Inhibiting BRAF/EGFR/MEK suppresses cancer stemness and drug resistance of primary colorectal cancer cells' has been published in Oncotarget.
Weiterlesen »
Copycat nutrient leaves pancreatic tumors starving, may inform cancer treatmentA study led by scientists at Sanford Burnham Prebys suggests an entirely new approach to treat pancreatic cancer. The research shows that feeding tumors a copycat of an important nutrient starves them of the fuel they need to survive and grow. The method, described in the journal Nature Cancer, has been used in early clinical trials for lung cancer. However, the unique properties of pancreatic cancer may make the strategy an even stronger candidate in the pancreas.
Weiterlesen »
Clinical trial finds herbal medicine Sailuotong effective for brain health in older peopleWestern Sydney University's NICM Health Research Institute has led a world-first clinical trial in Australia that offers new hope in the treatment of mild cognitive impairment (MCI) among older people. The trial's results, published in the journal Alzheimer's and Dementia, signal the efficacy and safety of Sailuotong (SLT), a novel herbal extract, as a potential treatment for MCI.
Weiterlesen »
Large clinical trial identifies best strategy to prevent life-threatening health care-associated ICU infectionsA large multi-state study by the Centers for Disease Control and Prevention, the Harvard Pilgrim Health Care Institute, HCA Healthcare, and the University of California, Irvine has found that a nasal antibiotic ointment, mupirocin, which is currently used daily for intensive care unit (ICU) patients in only one-third of U.S. hospitals, is highly effective at preventing Staphylococcus aureus infections in critically ill patients, outperforming an antiseptic solution.
Weiterlesen »
Adam Smith Institute welcomes Keir Starmer speech as ‘positive vision’KEIR Starmer’s conference speech has been welcomed by one of the UK’s most influential right-wing think tanks for setting out a “serious,…
Weiterlesen »